MMRi71, a novel small-molecule compound with dual targeting of MDM4/FTH1, not only accumulates p53 proteins in wt-p53 bearing cancer cells, but also effectively kills leukemia cells that are p53 deficient. Here, TP53 is linked to leukemia.